COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Betacoronavirus
COVID-19
Cladribine
/ adverse effects
Coronavirus Infections
/ complications
Humans
Immunosuppressive Agents
/ adverse effects
Lymphopenia
/ chemically induced
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
/ complications
Pandemics
Pneumonia, Viral
/ complications
SARS-CoV-2
Severity of Illness Index
COVID-19
Multiple sclerosis
cladribine
prognosis
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
9
8
2020
medline:
26
9
2020
entrez:
9
8
2020
Statut:
ppublish
Résumé
Most cases of COVID-19 are considered mild, but patients with immunosuppressant treatment might be prone to severe courses of disease. Expert panels advise to delay treatment with cell-depleting MS therapies during the COVID-19 pandemic. We report a case of a patient with relapsing-remitting multiple sclerosis who developed COVID-19 pneumonia 2 weeks after the first week of cladribine therapy. Despite a severe lymphopenia (absolute lymphocyte count 240/µL), the patient had a moderate course of COVID-19. Apart from maximal supportive treatment, this could be due to cladribine reducing inflammatory response, which probably contributes considerably to severe courses of COVID-19 pneumonia.
Sections du résumé
BACKGROUND
Most cases of COVID-19 are considered mild, but patients with immunosuppressant treatment might be prone to severe courses of disease. Expert panels advise to delay treatment with cell-depleting MS therapies during the COVID-19 pandemic.
METHODS
We report a case of a patient with relapsing-remitting multiple sclerosis who developed COVID-19 pneumonia 2 weeks after the first week of cladribine therapy.
RESULTS
Despite a severe lymphopenia (absolute lymphocyte count 240/µL), the patient had a moderate course of COVID-19.
CONCLUSION
Apart from maximal supportive treatment, this could be due to cladribine reducing inflammatory response, which probably contributes considerably to severe courses of COVID-19 pneumonia.
Identifiants
pubmed: 32762488
doi: 10.1177/1352458520943783
doi:
Substances chimiques
Immunosuppressive Agents
0
Cladribine
47M74X9YT5
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1264-1266Commentaires et corrections
Type : CommentIn